- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06307665
Utvärdering av effektiviteten och säkerheten för PT027 jämfört med PT007 administrerat vid behov hos deltagare 12 till <18 år med astma (ACADIA)
En randomiserad, dubbelblind, multicenter, parallell grupp, fas IIIb 52 veckors studie som utvärderar effektiviteten och säkerheten för PT027 jämfört med PT007 administrerat vid behov hos deltagare 12 till <18 år med astma (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 99508
- Rekrytering
- Research Site
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85234
- Rekrytering
- Research Site
-
Phoenix, Arizona, Förenta staterna, 85016
- Rekrytering
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72202
- Avslutad
- Research Site
-
-
California
-
Huntington Beach, California, Förenta staterna, 92647
- Har inte rekryterat ännu
- Research Site
-
Huntington Beach, California, Förenta staterna, 92648
- Har inte rekryterat ännu
- Research Site
-
Long Beach, California, Förenta staterna, 90806
- Rekrytering
- Research Site
-
Long Beach, California, Förenta staterna, 90815
- Rekrytering
- Research Site
-
Madera, California, Förenta staterna, 93636
- Har inte rekryterat ännu
- Research Site
-
Mission Viejo, California, Förenta staterna, 92691
- Rekrytering
- Research Site
-
Moreno Valley, California, Förenta staterna, 92553
- Rekrytering
- Research Site
-
Orange, California, Förenta staterna, 92868
- Rekrytering
- Research Site
-
Redondo Beach, California, Förenta staterna, 90277
- Rekrytering
- Research Site
-
Riverside, California, Förenta staterna, 92506
- Rekrytering
- Research Site
-
San Diego, California, Förenta staterna, 92123
- Har inte rekryterat ännu
- Research Site
-
San Diego, California, Förenta staterna, 92123
- Rekrytering
- Research Site
-
San Francisco, California, Förenta staterna, 94143
- Indragen
- Research Site
-
Westminster, California, Förenta staterna, 92683
- Rekrytering
- Research Site
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80206
- Rekrytering
- Research Site
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19803
- Rekrytering
- Research Site
-
-
Florida
-
Destin, Florida, Förenta staterna, 32541
- Rekrytering
- Research Site
-
Jacksonville, Florida, Förenta staterna, 32207
- Rekrytering
- Research Site
-
Kendall, Florida, Förenta staterna, 33176
- Har inte rekryterat ännu
- Research Site
-
Largo, Florida, Förenta staterna, 33777
- Avslutad
- Research Site
-
Miami, Florida, Förenta staterna, 33144
- Rekrytering
- Research Site
-
Miami, Florida, Förenta staterna, 33145
- Rekrytering
- Research Site
-
Miami, Florida, Förenta staterna, 33185
- Rekrytering
- Research Site
-
Miami, Florida, Förenta staterna, 33142
- Rekrytering
- Research Site
-
Miami, Florida, Förenta staterna, 33183
- Rekrytering
- Research Site
-
Orlando, Florida, Förenta staterna, 32827
- Har inte rekryterat ännu
- Research Site
-
Pembroke Pines, Florida, Förenta staterna, 33026
- Rekrytering
- Research Site
-
Tampa, Florida, Förenta staterna, 33613
- Indragen
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Rekrytering
- Research Site
-
Columbus, Georgia, Förenta staterna, 31904
- Rekrytering
- Research Site
-
Fayetteville, Georgia, Förenta staterna, 30214
- Rekrytering
- Research Site
-
Snellville, Georgia, Förenta staterna, 30078
- Rekrytering
- Research Site
-
-
Idaho
-
Meridian, Idaho, Förenta staterna, 83646
- Indragen
- Research Site
-
-
Illinois
-
Normal, Illinois, Förenta staterna, 61761
- Rekrytering
- Research Site
-
River Forest, Illinois, Förenta staterna, 60305
- Indragen
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Rekrytering
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Rekrytering
- Research Site
-
Overland Park, Kansas, Förenta staterna, 66213
- Har inte rekryterat ännu
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Förenta staterna, 40217
- Rekrytering
- Research Site
-
Louisville, Kentucky, Förenta staterna, 40202
- Rekrytering
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, Förenta staterna, 70508
- Rekrytering
- Research Site
-
New Orleans, Louisiana, Förenta staterna, 70121
- Rekrytering
- Research Site
-
New Orleans, Louisiana, Förenta staterna, 70125
- Rekrytering
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, Förenta staterna, 21043
- Rekrytering
- Research Site
-
Lanham, Maryland, Förenta staterna, 20706
- Har inte rekryterat ännu
- Research Site
-
Silver Spring, Maryland, Förenta staterna, 20902
- Rekrytering
- Research Site
-
White Marsh, Maryland, Förenta staterna, 21162
- Rekrytering
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Har inte rekryterat ännu
- Research Site
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, Förenta staterna, 56001
- Aktiv, inte rekryterande
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64118
- Rekrytering
- Research Site
-
Kansas City, Missouri, Förenta staterna, 64108
- Indragen
- Research Site
-
St Louis, Missouri, Förenta staterna, 63108
- Rekrytering
- Research Site
-
-
Montana
-
Missoula, Montana, Förenta staterna, 59804
- Rekrytering
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Förenta staterna, 68510
- Rekrytering
- Research Site
-
Lincoln, Nebraska, Förenta staterna, 68516
- Rekrytering
- Research Site
-
Omaha, Nebraska, Förenta staterna, 68114
- Rekrytering
- Research Site
-
-
New Jersey
-
Newark, New Jersey, Förenta staterna, 07103
- Rekrytering
- Research Site
-
Newark, New Jersey, Förenta staterna, 07103
- Har inte rekryterat ännu
- Research Site
-
Northfield, New Jersey, Förenta staterna, 08225
- Rekrytering
- Research Site
-
Ocean City, New Jersey, Förenta staterna, 07712
- Rekrytering
- Research Site
-
Paramus, New Jersey, Förenta staterna, 07652
- Rekrytering
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87106
- Rekrytering
- Research Site
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Rekrytering
- Research Site
-
Cortland, New York, Förenta staterna, 13045
- Rekrytering
- Research Site
-
Hawthorne, New York, Förenta staterna, 10532
- Rekrytering
- Research Site
-
Hollis, New York, Förenta staterna, 11423
- Indragen
- Research Site
-
New York, New York, Förenta staterna, 10032
- Rekrytering
- Research Site
-
New York, New York, Förenta staterna, 11355
- Rekrytering
- Research Site
-
New York, New York, Förenta staterna, 10019
- Indragen
- Research Site
-
Rochester, New York, Förenta staterna, 14607
- Avslutad
- Research Site
-
The Bronx, New York, Förenta staterna, 10459
- Rekrytering
- Research Site
-
The Bronx, New York, Förenta staterna, 10461
- Rekrytering
- Research Site
-
Vestal, New York, Förenta staterna, 13850
- Rekrytering
- Research Site
-
Vestal, New York, Förenta staterna, 13850
- Indragen
- Research Site
-
Watertown, New York, Förenta staterna, 13601
- Rekrytering
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28277
- Indragen
- Research Site
-
Durham, North Carolina, Förenta staterna, 27705
- Har inte rekryterat ännu
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Har inte rekryterat ännu
- Research Site
-
Columbus, Ohio, Förenta staterna, 43205
- Har inte rekryterat ännu
- Research Site
-
Columbus, Ohio, Förenta staterna, 43228
- Rekrytering
- Research Site
-
Dayton, Ohio, Förenta staterna, 45424
- Rekrytering
- Research Site
-
Findlay, Ohio, Förenta staterna, 45840
- Rekrytering
- Research Site
-
Toledo, Ohio, Förenta staterna, 43617
- Rekrytering
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73120
- Rekrytering
- Research Site
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Rekrytering
- Research Site
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Har inte rekryterat ännu
- Research Site
-
Yukon, Oklahoma, Förenta staterna, 73099
- Rekrytering
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15241
- Rekrytering
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Rekrytering
- Research Site
-
Rock Hill, South Carolina, Förenta staterna, 29730
- Avslutad
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57105
- Rekrytering
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37232
- Rekrytering
- Research Site
-
-
Texas
-
Austin, Texas, Förenta staterna, 78759
- Rekrytering
- Research Site
-
Baytown, Texas, Förenta staterna, 77521
- Rekrytering
- Research Site
-
Beaumont, Texas, Förenta staterna, 77701
- Rekrytering
- Research Site
-
Beaumont, Texas, Förenta staterna, 77702
- Rekrytering
- Research Site
-
Bellaire, Texas, Förenta staterna, 77401
- Rekrytering
- Research Site
-
Corpus Christi, Texas, Förenta staterna, 78411
- Rekrytering
- Research Site
-
Corsicana, Texas, Förenta staterna, 75110
- Rekrytering
- Research Site
-
Dallas, Texas, Förenta staterna, 75231
- Rekrytering
- Research Site
-
Dallas, Texas, Förenta staterna, 75235
- Rekrytering
- Research Site
-
El Paso, Texas, Förenta staterna, 79912
- Rekrytering
- Research Site
-
Frisco, Texas, Förenta staterna, 75034
- Indragen
- Research Site
-
Houston, Texas, Förenta staterna, 77099
- Rekrytering
- Research Site
-
Houston, Texas, Förenta staterna, 77030
- Har inte rekryterat ännu
- Research Site
-
Houston, Texas, Förenta staterna, 77065
- Rekrytering
- Research Site
-
Kerrville, Texas, Förenta staterna, 78028
- Indragen
- Research Site
-
McKinney, Texas, Förenta staterna, 75069
- Rekrytering
- Research Site
-
San Antonio, Texas, Förenta staterna, 78229
- Rekrytering
- Research Site
-
San Antonio, Texas, Förenta staterna, 78215
- Rekrytering
- Research Site
-
San Antonio, Texas, Förenta staterna, 78249
- Har inte rekryterat ännu
- Research Site
-
Tyler, Texas, Förenta staterna, 75708
- Avslutad
- Research Site
-
-
Utah
-
West Jordan, Utah, Förenta staterna, 84088
- Rekrytering
- Research Site
-
-
Vermont
-
Burlington, Vermont, Förenta staterna, 05405
- Rekrytering
- Research Site
-
-
Virginia
-
Burke, Virginia, Förenta staterna, 22015
- Indragen
- Research Site
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98225
- Avslutad
- Research Site
-
Vancouver, Washington, Förenta staterna, 98664
- Rekrytering
- Research Site
-
-
-
-
-
Beijing, Kina, 100191
- Rekrytering
- Research Site
-
Beijing, Kina, 100050
- Rekrytering
- Research Site
-
Bengbu, Kina, 233004
- Rekrytering
- Research Site
-
Chengdu, Kina, 610066
- Rekrytering
- Research Site
-
Chongqing, Kina, 401122
- Rekrytering
- Research Site
-
Hohhot, Kina, 10050
- Rekrytering
- Research Site
-
Mianyang, Kina, 621000
- Rekrytering
- Research Site
-
Shanghai, Kina, 200433
- Rekrytering
- Research Site
-
Shanghai, Kina
- Rekrytering
- Research Site
-
Shanghai, Kina, 200062
- Rekrytering
- Research Site
-
Shantou, Kina, 515041
- Rekrytering
- Research Site
-
Shenyang, Kina, 110004
- Rekrytering
- Research Site
-
Shenzhen, Kina, 518026
- Rekrytering
- Research Site
-
Suzhou, Kina, 215002
- Rekrytering
- Research Site
-
Taizhou, Kina, 318000
- Rekrytering
- Research Site
-
Tianjin, Kina, 300211
- Rekrytering
- Research Site
-
Tianjin, Kina, 300134
- Rekrytering
- Research Site
-
Tianjin, Kina, 300050
- Rekrytering
- Research Site
-
Wuhan, Kina, 430000
- Rekrytering
- Research Site
-
Yanji, Kina, 133000
- Rekrytering
- Research Site
-
Yantai, Kina, 264000
- Rekrytering
- Research Site
-
Zhongshan, Kina, 528400
- Rekrytering
- Research Site
-
-
-
-
-
Chihuahua City, Mexiko, 31000
- Rekrytering
- Research Site
-
Chihuahua City, Mexiko, 31238
- Rekrytering
- Research Site
-
Guadalajara, Mexiko, 44100
- Rekrytering
- Research Site
-
Guadalajara, Mexiko, 44500
- Rekrytering
- Research Site
-
Monterrey, Mexiko, 64465
- Rekrytering
- Research Site
-
-
-
-
-
Durban, Sydafrika, 4001
- Rekrytering
- Research Site
-
Durban, Sydafrika, 3630
- Rekrytering
- Research Site
-
Durban, Sydafrika, 4092
- Rekrytering
- Research Site
-
Krugersdorp, Sydafrika, 1739
- Rekrytering
- Research Site
-
Middelburg, Sydafrika, 1055
- Rekrytering
- Research Site
-
Panorama, Sydafrika, 7500
- Rekrytering
- Research Site
-
Somerset West, Sydafrika, 7130
- Har inte rekryterat ännu
- Research Site
-
Welkom, Sydafrika, 9460
- Rekrytering
- Research Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Andra namn:
|
|
Aktiv komparator: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
Tidsram: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
Tidsram: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
Tidsram: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
Tidsram: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Tidsram: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D6934C00001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .